Sign Up for Email AlertsSign Up Today
William Blair & Co.Y. Katherine Xu, Ph.D.
Griffin SecuritiesKeith A. Markey, Ph.D., M.B.A.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a late-stage clinical company developing therapeutics focused on the gut microbiome. The Company's lead candidates poised for Phase 3 development are: (1) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and (2) SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea (AAD) and the emergence of antibiotic-resistant organisms. The Company is also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria (PKU).View Profile
Synthetic Biologics, Inc.
Investor Relations Department
T: (301) 417-4364
Corporate Stock Transfer, Inc.
3200 Cherry Creek Drive South
Denver, CO 80209
T: (303) 282-4800